CORONAVIRUS

Will medical tourism survive covid-19?

Malaysia had big plans for its medical tourism industry in 2020—only for the pandemic to hit. Megan Tatum reports on a sector full of profit and promise that is now full of uncertainty.

Megan Tatum freelance journalist

Earlier this year, Lee Kim Siea, a plastic and reconstructive surgeon, had been due to travel to Indonesia with the Malaysian government. He had been invited to appear at an annual showcase of Malaysia’s healthcare facilities. It was an opportunity to build on the 30% of patients at his private clinic in the state of Penang who travel there from overseas—a proportion that has been increasing steadily for the last 15 years, he says. A “sizeable following” come from Indonesia, and others fly in from the Middle East, Europe, and Australia.

The event in Indonesia was organised by Malaysia Healthcare Travel Council (MHTC), the Malaysian government’s medical tourism arm, in what was expected to be a record breaking year for international healthcare travel. In 2019, each week had brought news of an addition to Malaysia’s growing list of private hospitals.

By the start of 2020, 15 000 beds were ready for the anticipated influx of international patients. The Malaysian government predicted that two million international visitors—an expected 33% rise on 2019—would arrive for medical treatment as part of its well promoted Year of Healthcare Travel.1

But in March all that came to a halt, when the Malaysian government instigated a lockdown to curb the growing number of covid-19 infections.

For hospitals that meant all but essential healthcare was prohibited. With international borders closing all over the world, it was a hammer blow to Malaysia’s medical tourism dream.

Across the world it’s a similar story. The medical tourism market, worth up to $87.5 billion (£70 billion, €77 billion) annually, is expected to shrink until 2021 as patients avoid unnecessary travel.2 At Bumrungrad International Hospital in Thailand, where half of patients come from overseas, experts are predicting a 28% drop in revenues by the end of 2020.3

But Malaysia hopes that strong government support for the private healthcare industry, coupled with its swift and strict response to the pandemic, could pave the way for a far quicker recovery in Malaysia than elsewhere.

**Government backing**

Between 2011 and 2018 the number of international tourists travelling to Malaysia for medical treatment doubled from 643 000 to 1.2 million, with visitors arriving from China, the UK, and the US.

Central to this growth has been a model of public-private partnership rarely seen in medical tourism. Noting the growth of the sector in nearby Thailand and Singapore, the Malaysian government launched targeted tax allowances and incentives for private healthcare that fuelled 10 billion ringgit (£1.9 billion, €2.10 billion) of private investment in the sector from 2011 to 2018.

The MHTC has also aggressively marketed the country’s facilities overseas. It has forged agreements to designate Malaysia as a healthcare destination of choice with the governments of Kazakhstan, Libya, and Oman, among others.4 5

The team at Prince Court Medical Centre in Kuala Lumpur, where 30% of patients are from overseas, has received patients for open heart surgery from Brunei as a direct result of government level discussions, says commercial director Vincent Wan. The MHTC has become the “backbone” of the private healthcare industry, he says. “They’ve put Malaysia on the world map, which is in contrast to most countries where private hospitals must market the sector on their own.”

Government backing has been instrumental in shaping the style of medical tourism for which Malaysia is becoming known, says Shujaat Ali, the founder of online platform Medical Travel Market. “They refer to it as the ‘whole medical tourism experience,’ which not many countries have invested in, and which involves connecting airlines and hotels with hospitals to create a complete package.” In 2018, for example, the MHTC reached an agreement with airline Air Asia to promote one another as the preferred destination and carrier for medical tourism.6

**Safety and affordability**

The most common treatments for which patients come to Malaysia are in orthopaedics, cardiology, IVF, neurology, and oncology, according to the MHTC, and affordable cosmetic surgery is a further draw. For patients whose home countries have less well developed healthcare systems, such as Indonesia, Malaysia offers quality and safety, but at a lower cost than nearby alternatives. Procedures in Malaysia cost up to 40% less than their equivalent in Singapore, for example.7

In a 2019 paper looking at the motivations among Indonesians travelling to Malaysia for treatment, patients cited misdiagnosis and poor safety standards from their domestic providers, as well as slower, less
efficient service. One patient claimed to have been given a “50/50 chance to live” in Indonesia after a diagnosis of hepatitis, before recovering fully following treatment in Penang.

Malaysia has worked to leverage this appeal. In 2019 revenues from medical tourism accounted for 7.9% of total tourist revenues in the country, according to authorities, worth 1.5 billion Malaysian ringgit (£350 million, €388 million). From a standing start that now puts it close on the heels of neighbouring Thailand, the long established market leader in the region, which has revenues of around £480 million from medical tourists.

Although the US remains the largest international market for medical tourists, accounting for around 36% of total spend, countries across the Asia Pacific region have recorded the fastest growth, at a predicted growth rate of 15.5% between 2017 and 2023.

Treatment in Asia is up to 90% cheaper than private healthcare in the US. According to the MHTC, a coronary artery bypass graft that would cost $92 000 in the US, costs less than $10 000 in India, for example. Coupled with a steep reduction in the cost of long haul air travel, the region has successfully broadened the appeal of medical tourism beyond just the most affluent customers.

**Uncertain future**

But all that was before the pandemic. The uncertainty of covid-19, lockdowns, border restrictions, and social distancing has stalled international travel. The UN World Tourism Organisation estimates that the travel industry could decline by 60% to 80% by the end of 2020, calling it the “worst crisis that international tourism has faced since records began.”

It says Asia and the Pacific have been the regions hardest hit, with a loss of 33 million tourists.

For Lee Kim Sia and for other private healthcare providers, the closure of borders has meant a precipitous drop in revenues. At one private hospital in Penang, revenues fell 66% in April and 55% in May as foreign patients dropped to zero and local patients postponed all but essential treatment.

Yet Asia’s relative success in containing the virus means it could recover faster than other regions. “Countries in southeast Asia that have kept the infection rates very low will definitely present themselves as covid-safe destinations,” says Gary Bowerman, an independent travel analyst specialising in Asia. “Success in suppressing the virus, and—very importantly—implementing and maintaining rigorous testing and tracing is already proving important in tourism promotion and decision making.”

Malaysia has already proven itself strong on this front, recording around 8500 cases and 121 deaths at the time of writing, despite its control. Bowerman says that how governments handle the pandemic will “not only provides reassurance to travellers when selecting a destination in the post-pandemic era, but also demonstrates proven covid-related expertise, learnings, and capacities should there be tidal rises for infection rates once travel is phased back, and—more importantly—in the event of a more sustained second or third wave.”

For now, it’s still a hazy future for Lee Kim Sia. Rather than promoting its services at an international expo, he has spent the last three months combing through old international patient records, sending WhatsApp messages “to remind them we’re here,” and offering free video consultations. His business can only wait to see if it will survive in the new covid world.

**Competing interests** I have read and understood the BMJ Group policy on declaration of interests and have no relevant interests to declare.

Provenance and peer review: Commissioned, not externally peer reviewed.


This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.